Today we learned that Lilly will close their Singapore R&D facility. This facility was focused on drug discovery in cancer and diabetes.
I leave it to the powers that be within Lilly to determine whether this is a wise decision or not. However, as my colleague told me this morning, “Yes, but they still need pipeline.” Indeed, this is quite true. There are only so many companies like King around to acquire.